Diminishes the risk of cardiac insufficiency  


COMPOSITION: Atorvastatin Calcium IP 20 mg + Clopidogrel (as Bisulphate) IP 75 mg + Aspirin IP 75 mg

  • Improves inflammatory responses, accelerates platelet function & blood coagulation system after coronary artery bypass grafting.
  • Addition of clopidogrel decreases mortality rates by reducing the incidence of thrombotic vascular events in patients with congestive heart failure.
  • Reduces the risk of stroke and also does not increase the risk of hemorrhage in patients with transient ischemic attack.
  • Markedly inhibits (ADP)-mediated platelet aggregation and collagen-induced aggregation in patients with myocardial infarction.


  • Acute & chronic coronary syndrome
  • Thromboembolic Stroke
  • Recurrent Ischemic Stroke
  • Myocardial Infarction
  • Angina
  • Atherosclerosis





  • Drug class: HMG-CoA reductase inhibitors (statins)
  • Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD.
  • Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase by doing so, helps decrease cholesterol production in the liver. 
  • Atorvastatin also increases the number of LDL receptors on the surface of hepatic cells.


  • Clopidogrel is a prodrug, which needs to be metabolized in the liver into active metabolites.
  • Clopidogrel efficiently reduces ADP-induced platelet aggregation (a key phenomenon in atherosclerosis & CVD) and prolongs bleeding time and is a safe and efficacious antiplatelet drug.


  • Drug Class: NSAIDs
  • The most widely tested antiplatelet regimen was aspirin. The benefit of low-dose aspirin therapy for the secondary prevention of serious cardiovascular events is clear.
  • Aspirin has long been the therapeutic foundation of the secondary prevention of CVD, to which contemporary drugs such as statins, and other antithrombotics have been added.


  • Aspirin and clopidogrel are antiplatelet agents that display good antithrombotic activity.Clopidogrel in combination with aspirin is the current “gold standard” for reducing cardiovascular events.
  • Clopidogrel plus aspirin can reduce the relative risk of adverse cardiovascular events by 20%, compared with aspirin alone.
  • Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. But, statin (Atorvastatin) quickly decreases thrombosis risk and inflammation, and these effects may balance the loss of clopidogrel efficacy.